Michael Mamoun, M.D.


Michael Mamoun

Michael Mamoun, M.D.

Executive Medical Director
Board Certified in General & Adult Psychiatry
Board Certified in Addiction Medicine
Member, American Psychiatric Association
Member, American Society for Functional Neuroradiology

Michael Mamoun, M.D. is a physician and scientist. In addition to his clinical practice, Dr Mamoun has been involved in neuroscience research for almost 20 years. He is board-certified by the American Board of Psychiatry and Neurology and by the American Board of Addiction Medicine. Doctor Mamoun completed his residency training at the Neuropsychiatric Institute of the UCLA Medical Center. UCLA is consistently ranked in the top #1-3 institutions for psychiatry training internationally. He has been consecutively voted as a top doctor by US News & Health Report and by Los Angeles Magazine.

Clinically, Dr. Mamoun is experienced in treating the entire spectrum of mental health conditions, including depression, anxiety, bipolar disorder, and ADHD. He is also skilled in treating substance abuse disorders, including smoking, prescription drug dependence & recreational drug use. He routinely treats a wide range of conditions, ranging from simple depression to very challenging and treatment-refractory neuropsychiatric conditions referred  by colleagues nationwide. Dr. Mamoun also provides educational guidance and supervision to numerous psychiatrists.

In addition to traditional psychiatric treatment, when clinically-indicated, he sometimes incorporates modern technological tools in order to assist in diagnosis and treatment of challenging cases. This includes pharmaco-genetic testing, sophisticated neuroimaging, and fMRI-guided TMS. His experience in neuroimaging includes: CT, PET, MRI, DTI, MRS, and fMRI (functional MRI) – including 3D MPRage, Resting BOLD, and ASL. He is one of the first psychiatrists in the country to collaborate with neurologists and neuroradiologists in offering neuroimaging-based, fMRI-guided multi-site TMS (magnetic stimulation of the brain) in order to treat psychiatric conditions in a novel way.

Academically, Doctor Mamoun has been involved in neuroimaging brain research dating all the way back to his undergraduate years. While there, he researched human memory systems under Dr. Neal Cohen (Beckman Institute), whose lab studied the patient “H.M.” (Link to more info) H.M. is widely regarded as the best-known patient in the history of neuroscience. More recently, Dr. Mamoun’s research focused on nicotine addiction through the Brentwood Biomedical Research Institute in affiliation with the UCLA and VA Medical Centers. His research projects utilize brain imaging in order to better understand the nature of psychiatric conditions and drug addictions. One such study, recently published in JAMA (Journal of the American Medical Association) Psychiatry (Link), showed how functional neuroimaging can be used to help predict psychiatric treatment response. It has since been cited in numerous studies and conferences.

Dr. Mamoun has previously served as the Director of Psychiatric Services at Homeless Healthcare Los Angeles and has volunteered at the non-profit Venice Family Clinic.


Link to Patient Reviews on Vitals.com

Link to Patient Reviews on Yelp.com
Link to Patient Reviews on Healthgrades.com

 Link to Recent Published Research Studies


Recently published research studies:

March 2017:
Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [11C]DAA1106 PET Study
Journal of Neuropsychopharmacology

July 2016:
Nicotinic acetylcholine receptor availability in cigarette smokers: effect of heavy caffeine or marijuana use.
Journal of Psychopharmacology

April 2015:
Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date
Journal of CNS Drugs

August 2014:
Radiation dosimetry and biodistribution of the translocator protein radiotracer [(11)C]DAA1106 determined with PET/CT in healthy human volunteers.
Journal of Nuclear Medicine and Biology

May 2014:
Brain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment: A Randomized Trial.
JAMA (Journal of the American Medical Association) Psychiatry. MRI & PET brain imaging study.

July 2013:
Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density.
Neuropsychopharmacology. 2013 Jul;38(8):1548-56.  PET neuroimaging study.

June 2013:
Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers
International Journal of Neuropsychopharmacology. 2013 Jun;16(5):957-66. PET neuroimaging study.



patients choice awards